Latest Breaking News On - Activity impairment questionnaire - Page 2 : comparemela.com

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary ...

The STRIDE study did not meet its primary or secondary efficacy endpoint

Evaluating Work Productivity, Efficacy and Safety of Tildrakizumab in Patients With Plaque Psoriasis

Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.

Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 Reneo Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the.

Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

Tildrakizumab Significantly Improves Work Productivity in Moderate to Severe Plaque Psoriasis

Tildrakizumab significantly improved work productivity and reduced work activity impairment in patients with moderate to severe plaque psoriasis, highlighting this treatment's quality of life benefits.